AOA Dx Announces Initial Validation of Novel Tumor Gangliosides as Promising Diagnostic Markers for Early Detection of Ovarian Cancer
AOA Dx announces initial validation of GD2 and GD3 tumor marker gangliosides as novel diagnostic markers for early detection of ovarian cancer. AOA Dx results will be presented at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.